EcoDrugPlus

Prostaglandin E2 Receptor Ep2 Subtype-Like

Ensembl ID : ENSCGOG00000000388
Gene Symbol: LOC115016879
3 Cross references
203 Possible Orthologues:

Prostaglandin E2 Receptor Ep4 Subtype-Like

Ensembl ID : ENSCGOG00000009318
Gene Symbol: LOC115016415
3 Cross references
202 Possible Orthologues:

Prostaglandin E2 Receptor Ep4 Subtype-Like

Ensembl ID : ENSCGOG00000021925
Gene Symbol: LOC115013406
3 Cross references
202 Possible Orthologues:

Prostaglandin F Receptor

Ensembl ID : ENSCGOG00000014552
Gene Symbol: PTGFR
3 Cross references
195 Possible Orthologues:

Prostaglandin I2 Receptor

Ensembl ID : ENSCGOG00000008783
Gene Symbol: PTGIR
3 Cross references
188 Possible Orthologues:

Prostaglandin-Endoperoxide Synthase 1

Ensembl ID : ENSCGOG00000012766
Gene Symbol: PTGS1
3 Cross references
196 Possible Orthologues:

Prostaglandin-Endoperoxide Synthase 1

Ensembl ID : ENSCGOG00000013756
Gene Symbol: PTGS1
3 Cross references
196 Possible Orthologues:

Prostaglandin-Endoperoxide Synthase 2

Ensembl ID : ENSCGOG00000001550
Gene Symbol: PTGS2
3 Cross references
213 Possible Orthologues:

Proteasome 20s Subunit Alpha 1

Ensembl ID : ENSCGOG00000010008
Gene Symbol: PSMA1
3 Cross references
271 Possible Orthologues:

Proteasome 20s Subunit Alpha 2

Ensembl ID : ENSCGOG00000009400
Gene Symbol: PSMA2
3 Cross references
278 Possible Orthologues:

Proteasome 20s Subunit Alpha 4

Ensembl ID : ENSCGOG00000004630
Gene Symbol: PSMA4
3 Cross references
211 Possible Orthologues:

Proteasome 20s Subunit Alpha 5

Ensembl ID : ENSCGOG00000007933
Gene Symbol: PSMA5
3 Cross references
212 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).